Home » Stocks » MOLN

Molecular Partners AG (MOLN)

Stock Price: $20.40 USD 0.57 (2.85%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 656.02M
Revenue (ttm) 10.62M
Net Income (ttm) -71.32M
Shares Out 32.16M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $20.40
Previous Close $19.84
Change ($) 0.57
Change (%) 2.85%
Day's Open 20.10
Day's Range 19.84 - 20.40
Day's Volume 5,429
52-Week Range 18.00 - 21.33


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cowen & Co initiated coverage on Molecular Partners (NASDAQ: MOLN) with an Outperform rating and a Price Target of $50, implying an upside potential of more than 150%. The company and its partner Novart...

2 weeks ago - Benzinga

ZURICH-SCHLIEREN, Switzerland, July 08, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR

3 weeks ago - GlobeNewsWire

Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial pu...

1 month ago - ACCESSWIRE

Molecular Partners AG has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

While the focus in Switzerland, and elsewhere, has been primarily on vaccines in the past few months, a new medication may also offer hope in the fight against Covid-19. This is what we know about this ...

3 months ago - The Local

Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients.

3 months ago - BioSpace

About MOLN

Molecular Partners is a clinical stage biopharmaceutical company applying our pioneering DARPin® product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology. Our DARPin platform, which is designed using ankyrin repeat proteins, allows us to build product candidates with multiple mechanisms of action to address complex biological problems, while potentially offering patients products with higher efficacy and fewer adverse events. We believe that DARPin therapeutics represent a novel class... [Read more...]

IPO Date
Jun 16, 2021
Patrick Amstutz
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, MOLN's revenue was 9.34 million, a decrease of -54.16% compared to the previous year's 20.38 million. Losses were -62.76 million, 73.0% more than in 2019.

Financial numbers in millions CHF.
Financial Statements